KFDA Approves Atacand for Treatment of Heart Failure

Published: 2005-04-06 06:58:00

Updated: 2005-04-06 06:58:00

AstraZeneca Korea announced that Atacand (candesarten cilexetil), an angiotensin receptor blocker (ARB) for the treatment of hypertension, has been approved by the Korea Food and Drug Administration (KFDA) for the treatment of heart failure to reduce the cardiovascular mortality and hospitalizati...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK